世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

2030年までの欧州オルガノイド市場予測-地域別分析-臓器タイプ別(腸、肝臓、胃、膵臓、肺、脳、腎臓、その他)、用途別(生物疾患開発、感染症病理、再生医療、創薬・個別化医療、薬毒性・有効性試験、その他)、供給源別(多能性幹細胞、臓器特異的成体幹細胞)、タイプ別(器具、消耗品、サービス)


Europe Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery and Personalized Medicine, Drug Toxicity and Efficacy Testing, and Others), Source (Pluripotent Stem Cell and Organ Specific Adult Stem Cell), and Type (Instruments, Consumables, and Services)

ヨーロッパのオルガノイド市場は、2022年の8億4,219万米ドルから2030年には40億8,052万米ドルに成長すると予測されている。2022年から2030年までの年平均成長率は21.8%と推定される。 欧州オルガノイド市場に... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
The Insight Partners
ザ・インサイトパートナーズ
2023年11月20日 US$3,000
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
99 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

ヨーロッパのオルガノイド市場は、2022年の8億4,219万米ドルから2030年には40億8,052万米ドルに成長すると予測されている。2022年から2030年までの年平均成長率は21.8%と推定される。

欧州オルガノイド市場における個別化薬剤の採用拡大

個別化医療は精密医療とも呼ばれ、予測される反応や病気のリスクに基づいて個々の患者に合わせた処置や薬剤を実践する医療モデルである。個別化医療連合(PMC)が発表した研究によると、個別化医療は2005年にはFDAが承認した新規分子実体のわずか5%に過ぎなかったが、2016年には25%以上を占めるようになった。さらに、全化合物の42%、パイプラインにあるがん領域の化合物の73%が個別化医療になる可能性がある。さらに、バイオ医薬品企業は、個別化医薬品への研究開発投資を過去5年間でほぼ倍増させており、今後5年間で33%増加すると見られている。バイオ医薬品研究者も、今後5年間で個別化医薬品の開発が69%増加すると予測している。

個別化薬物療法を生み出すためのオルガノイドの導入は、患者ケアを改善するエキサイティングな機会を提供する。さらに、薬剤師は、精密医療について積極的に教育し、意識を高めることで、個別化医薬品の需要拡大に不可欠な役割を果たしている。最近の調査では、消費者の50%以上がカスタマイズされた製品やサービスの購入に関心を持っていることが明らかになった。この需要は、医薬品をより安全で効果的なものにするため、よりオーダーメイドの治療法を開発するよう製薬研究を説得している。

個別化がん医療は、腫瘍のゲノム的特徴に従って、患者ごとに効果的な治療戦略を調整するアプローチである。前臨床におけるゲノムの薬物反応予測の機能的側面を確認するために、個別化腫瘍モデリングの研究に対する需要が高まっている。遺伝子-薬物関連治療、新規治療法の同定、患者の転帰予測などの観点から、個別化がん医療における腫瘍オルガノイドの応用が、数多くの研究で強調されている。

個別化がん治療では、それぞれの患者に特異的な治療が適用される。元の腫瘍と類似した特徴を持つ個別化腫瘍モデルを用いることで、患者の薬物反応を正確に予測できる可能性がある。腫瘍オルガノイドモデルには、既存のモデルよりも元の腫瘍の分子・細胞組成を保存できるなど、いくつかの利点がある。これらの利点は、特に前臨床薬物スクリーニングや選択された治療レジメンに対する患者の反応予測など、個別化癌治療における腫瘍オルガノイドの大きな可能性を強調するものである。

欧州オルガノイド市場概要

欧州オルガノイド市場は、ドイツ、フランス、イタリア、英国、スペイン、その他の欧州に細分化される。この地域の市場成長は、組織工学と臓器移植の需要の高まり、疾患モデリング、遺伝子変異、腫瘍モデリングのためのオルガノイド採用の増加、オルガノイドに関する研究活動の活発化に関連している。加えて、資金調達や官民投資の増加といった要因も、この地域の今後数年間にさらなるビジネスチャンスをもたらすだろう。

欧州オルガノイド市場の売上高と2030年までの予測 (百万米ドル)

欧州オルガノイド市場のセグメンテーション

欧州のオルガノイド市場は、臓器の種類、タイプ、用途、供給源、国に区分される。

臓器タイプに基づき、欧州オルガノイド市場は腸、肝臓、胃、膵臓、肺、脳、腎臓、その他に区分される。腸セグメントが2022年の欧州オルガノイド市場で最大のシェアを占めている。

タイプ別では、欧州オルガノイド市場は機器、消耗品、サービスに区分される。消耗品セグメントは2022年に欧州オルガノイド市場で最大のシェアを占めた。

用途別では、欧州オルガノイド市場は発生生物学的疾患、感染症病理学、再生医療、薬剤毒性・有効性試験、創薬・個別化医療、その他に区分される。発生生物学的疾患分野が2022年の欧州オルガノイド市場で最大のシェアを占めた。

供給源に基づき、欧州オルガノイド市場は多能性幹細胞と臓器特異的成体幹細胞に二分される。多能性幹細胞セグメントは2022年の欧州オルガノイド市場でより大きなシェアを占めた。

国別では、欧州オルガノイド市場はドイツ、フランス、イギリス、イタリア、スペイン、その他の欧州に区分される。ドイツは2022年の欧州オルガノイド市場を支配した。

Cellsce社、Definigen社、Hubrecht Organoid Technology社、InSphero社、Merck KGaA社、STEMCELL Technologies Inc社、Thermo Fisher Scientific Inc社は、欧州オルガノイド市場で事業を展開している大手企業である。

ページTOPに戻る


目次

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Europe Key Insights
2.2 Europe Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Organoids Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
5. Europe Organoids Market - Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Increasing Demand for Tumor Modeling and Biobanking
5.1.2 Growing Adoption of Personalized Drugs
5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
5.2 Key Market Restraints:
5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
5.2.2 Dearth of Skilled Professionals
5.3 Key Market Opportunities:
5.3.1 Focus on Drug Discovery Activities
5.4 Future Trends:
5.4.1 Combining Organoid with Organ-On-A-Chip
5.5 Impact Analysis:
6. Organoids Market – Europe Market Analysis
6.1 Europe Organoids Market Revenue (US$ Mn), 2022 – 2030
7. Europe Organoids Market – Revenue and Forecast to 2030 – by Organ Type
7.1 Overview
7.2 Europe Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
7.3 Stomach
7.3.1 Overview
7.3.2 Stomach: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Intestine
7.4.1 Overview
7.4.2 Intestine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Liver
7.5.1 Overview
7.5.2 Liver: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Pancreas
7.6.1 Overview
7.6.2 Pancreas: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Lung
7.7.1 Overview
7.7.2 Lung: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Brain
7.8.1 Overview
7.8.2 Brain: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Kidney
7.9.1 Overview
7.9.2 Kidney: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Organoids Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Europe Organoids Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Developmental Biology
8.3.1 Overview
8.3.2 Developmental Biology: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Disease Pathology of Infectious Disease
8.4.1 Overview
8.4.2 Disease Pathology of Infectious Disease: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Regenerative Medicine
8.5.1 Overview
8.5.2 Regenerative Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Drug Toxicity and Efficacy Testing
8.6.1 Overview
8.6.2 Drug Toxicity and Efficacy Testing: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Drug Discovery and Personalized Medicine
8.7.1 Overview
8.7.2 Drug Discovery and Personalized Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Organoids Market – Revenue and Forecast to 2030 – by Source
9.1 Overview
9.2 Europe Organoids Market Revenue Share, by Source 2022 & 2030 (%)
9.3 Pluripotent Stem Cells
9.3.1 Overview
9.3.2 Pluripotent Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Organ-specific Adult Stem Cells
9.4.1 Overview
9.4.2 Organ-specific Adult Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Organoids Market – Revenue and Forecast to 2030 – by Type
10.1 Overview
10.2 Europe Organoids Market Revenue Share, by Type 2022 & 2030 (%)
10.3 Instruments
10.3.1 Overview
10.3.2 Instruments: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Consumables
10.4.1 Overview
10.4.2 Consumables: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
11. Europe Organoids Market - Country Analysis
11.1 Europe Organoids Market: Overview
11.1.1 Europe Organoids Market by Country
11.1.1.1 Germany
11.1.1.1.1 Overview
11.1.1.1.2 Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.3 Germany Organoids Market, by Organ Type
11.1.1.1.4 Germany Organoids Market, by Application
11.1.1.1.5 Germany Organoids Market, by Source
11.1.1.1.6 Germany Organoids Market, by Type
11.1.1.2 UK
11.1.1.2.1 Overview
11.1.1.2.2 UK Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.3 UK Organoids Market, by Organ Type
11.1.1.2.4 UK Organoids Market, by Application
11.1.1.2.5 UK Organoids Market, by Source
11.1.1.2.6 UK Organoids Market, by Type
11.1.1.3 France
11.1.1.3.1 Overview
11.1.1.3.2 France Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.3 France Organoids Market, by Organ Type
11.1.1.3.4 France Organoids Market, by Application
11.1.1.3.5 France Organoids Market, by Source
11.1.1.3.6 UK Organoids Market, by Type
11.1.1.4 Italy
11.1.1.4.1 Overview
11.1.1.4.2 Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.4.3 Italy Organoids Market, by Organ Type
11.1.1.4.4 Italy Organoids Market, by Application
11.1.1.4.5 Italy Organoids Market, by Source
11.1.1.4.6 Italy Organoids Market, by Type
11.1.1.5 Spain
11.1.1.5.1 Overview
11.1.1.5.2 Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.5.3 Spain Organoids Market, by Organ Type
11.1.1.5.4 Spain Organoids Market, by Application
11.1.1.5.5 Spain Organoids Market, by Source
11.1.1.5.6 Spain Organoids Market, by Type
11.1.1.6 Rest of Europe
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.6.3 Rest of Europe Organoids Market, by Organ Type
11.1.1.6.4 Rest of Europe Organoids Market, by Application
11.1.1.6.5 Rest of Europe Organoids Market, by Source
11.1.1.6.6 Rest of Europe Organoids Market, by Type
12. Pre & Post COVID-19 Impact
12.1 Pre & Post COVID-19 Impact
13. Europe Organoids Market Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Europe Organoids Market, Key Company Profiles
14.1 STEMCELL Technologies Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Cellesce Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Hubrecht Organoid Technology
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Definigen
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Thermo Fisher Scientific Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.7 InSphero
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
15. Appendix
15.1 About Us
15.2 Glossary of Terms

 

ページTOPに戻る


 

Summary

The Europe organoids market is expected to grow from US$ 842.19 million in 2022 to US$ 4,080.52 million by 2030. It is estimated to grow at a CAGR of 21.8% from 2022 to 2030.

Growing Adoption of Personalized Drugs in Europe Organoids Market

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.

The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.

Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

Europe Organoids Market Overview

The Europe organoids market is sub-segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. The regional market growth is associated with the rising demand for tissue engineering and organ transplantation; increasing adoption of organoids for disease modeling, gene mutation, and tumor modeling; and growing research activities on organoids. In addition, factors such as increased funding and public–private investments will likely add more opportunities in the coming years in the region.

Europe Organoids Market Revenue and Forecast to 2030 (US$ Million)

Europe Organoids Market Segmentation

The Europe organoids market is segmented into organ type, type, application, source, and country.

Based on organ type, the Europe organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the Europe organoids market in 2022.

Based on type, the Europe organoids market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the Europe organoids market in 2022.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the Europe organoids market in 2022.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the Europe organoids market in 2022.

Based on country, the Europe organoids market is segmented into the Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. Germany dominated the Europe organoids market in 2022.

Cellesce, Definigen, Hubrecht Organoid Technology, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe organoids market.



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Europe Key Insights
2.2 Europe Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Organoids Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
5. Europe Organoids Market - Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Increasing Demand for Tumor Modeling and Biobanking
5.1.2 Growing Adoption of Personalized Drugs
5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
5.2 Key Market Restraints:
5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
5.2.2 Dearth of Skilled Professionals
5.3 Key Market Opportunities:
5.3.1 Focus on Drug Discovery Activities
5.4 Future Trends:
5.4.1 Combining Organoid with Organ-On-A-Chip
5.5 Impact Analysis:
6. Organoids Market – Europe Market Analysis
6.1 Europe Organoids Market Revenue (US$ Mn), 2022 – 2030
7. Europe Organoids Market – Revenue and Forecast to 2030 – by Organ Type
7.1 Overview
7.2 Europe Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
7.3 Stomach
7.3.1 Overview
7.3.2 Stomach: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Intestine
7.4.1 Overview
7.4.2 Intestine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Liver
7.5.1 Overview
7.5.2 Liver: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Pancreas
7.6.1 Overview
7.6.2 Pancreas: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Lung
7.7.1 Overview
7.7.2 Lung: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Brain
7.8.1 Overview
7.8.2 Brain: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Kidney
7.9.1 Overview
7.9.2 Kidney: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Organoids Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Europe Organoids Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Developmental Biology
8.3.1 Overview
8.3.2 Developmental Biology: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Disease Pathology of Infectious Disease
8.4.1 Overview
8.4.2 Disease Pathology of Infectious Disease: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Regenerative Medicine
8.5.1 Overview
8.5.2 Regenerative Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Drug Toxicity and Efficacy Testing
8.6.1 Overview
8.6.2 Drug Toxicity and Efficacy Testing: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Drug Discovery and Personalized Medicine
8.7.1 Overview
8.7.2 Drug Discovery and Personalized Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Organoids Market – Revenue and Forecast to 2030 – by Source
9.1 Overview
9.2 Europe Organoids Market Revenue Share, by Source 2022 & 2030 (%)
9.3 Pluripotent Stem Cells
9.3.1 Overview
9.3.2 Pluripotent Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Organ-specific Adult Stem Cells
9.4.1 Overview
9.4.2 Organ-specific Adult Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Organoids Market – Revenue and Forecast to 2030 – by Type
10.1 Overview
10.2 Europe Organoids Market Revenue Share, by Type 2022 & 2030 (%)
10.3 Instruments
10.3.1 Overview
10.3.2 Instruments: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Consumables
10.4.1 Overview
10.4.2 Consumables: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
11. Europe Organoids Market - Country Analysis
11.1 Europe Organoids Market: Overview
11.1.1 Europe Organoids Market by Country
11.1.1.1 Germany
11.1.1.1.1 Overview
11.1.1.1.2 Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.3 Germany Organoids Market, by Organ Type
11.1.1.1.4 Germany Organoids Market, by Application
11.1.1.1.5 Germany Organoids Market, by Source
11.1.1.1.6 Germany Organoids Market, by Type
11.1.1.2 UK
11.1.1.2.1 Overview
11.1.1.2.2 UK Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.3 UK Organoids Market, by Organ Type
11.1.1.2.4 UK Organoids Market, by Application
11.1.1.2.5 UK Organoids Market, by Source
11.1.1.2.6 UK Organoids Market, by Type
11.1.1.3 France
11.1.1.3.1 Overview
11.1.1.3.2 France Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.3 France Organoids Market, by Organ Type
11.1.1.3.4 France Organoids Market, by Application
11.1.1.3.5 France Organoids Market, by Source
11.1.1.3.6 UK Organoids Market, by Type
11.1.1.4 Italy
11.1.1.4.1 Overview
11.1.1.4.2 Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.4.3 Italy Organoids Market, by Organ Type
11.1.1.4.4 Italy Organoids Market, by Application
11.1.1.4.5 Italy Organoids Market, by Source
11.1.1.4.6 Italy Organoids Market, by Type
11.1.1.5 Spain
11.1.1.5.1 Overview
11.1.1.5.2 Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.5.3 Spain Organoids Market, by Organ Type
11.1.1.5.4 Spain Organoids Market, by Application
11.1.1.5.5 Spain Organoids Market, by Source
11.1.1.5.6 Spain Organoids Market, by Type
11.1.1.6 Rest of Europe
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.6.3 Rest of Europe Organoids Market, by Organ Type
11.1.1.6.4 Rest of Europe Organoids Market, by Application
11.1.1.6.5 Rest of Europe Organoids Market, by Source
11.1.1.6.6 Rest of Europe Organoids Market, by Type
12. Pre & Post COVID-19 Impact
12.1 Pre & Post COVID-19 Impact
13. Europe Organoids Market Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Europe Organoids Market, Key Company Profiles
14.1 STEMCELL Technologies Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Cellesce Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Hubrecht Organoid Technology
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Definigen
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Thermo Fisher Scientific Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.7 InSphero
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
15. Appendix
15.1 About Us
15.2 Glossary of Terms

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

The Insight Partners社のバイオテクノロジー分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


The Insight Partners社はどのような調査会社ですか?


The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る